Boehringer Ingelheim's Nerandomilast Trial for Lung Fibrosis in Autoimmune Diseases
A clinical trial is underway to evaluate the efficacy of nerandomilast in patients with lung fibrosis related to systemic autoimmune rheumatic diseases.
Indication
Clinical and regulatory intelligence for Lung Fibrosis with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.